Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Drug-Specific Antibodies”

24 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 24 results

Not applicableStudy completedNCT06565364
What this trial is testing

Immunogenicity and Thrombotic Potential of Circulating Protamine-heparin Complexes in Cardiac Surgery Patients

Who this might be right for
ThrombocytopeniaAntibodies Drug Specific
Medical University of Vienna 160
Not applicableStudy completedNCT04898140
What this trial is testing

The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents

Who this might be right for
Covid19Respiratory Viral Infection
Moscow Department of Health 5,340
Early research (Phase 1)Looking for participantsNCT07082920
What this trial is testing

JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 140
Testing effectiveness (Phase 2)Looking for participantsNCT07136779
What this trial is testing

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

Who this might be right for
Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc 310
Testing effectiveness (Phase 2)Looking for participantsNCT06525298
What this trial is testing

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Who this might be right for
Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency
Eisbach Bio GmbH 144
Testing effectiveness (Phase 2)Study completedNCT02001623
What this trial is testing

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Who this might be right for
Ovary CancerCervix CancerEndometrium Cancer+5 more
Seagen Inc. 195
Not applicableLooking for participantsNCT02912143
What this trial is testing

German Pediatric Hemophilia Research Database

Who this might be right for
Hemophilia AHemophilia BChildren+1 more
Goethe University 800
Early research (Phase 1)Temporarily pausedNCT03859752
What this trial is testing

TR1801-ADC in Patients With Tumors That Express c-Met

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Open Innovation Partners, Inc. 15
Post-approval studies (Phase 4)Active Not RecruitingNCT04665310
What this trial is testing

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

Who this might be right for
Kidney Disease, End-StageDonor Specific AntibodiesAcute Rejection of Renal Transplant
The Methodist Hospital Research Institute 46
Testing effectiveness (Phase 2)WithdrawnNCT05582694
What this trial is testing

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Who this might be right for
Multi-Drug Resistant Hiv-1 InfectionHIV-1 Infection
National Institute of Allergy and Infectious Diseases (NIAID)
Early research (Phase 1)Active Not RecruitingNCT04662580
What this trial is testing

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Janssen Research & Development, LLC 183
Not applicableUnknownNCT05606302
What this trial is testing

A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China

Who this might be right for
Drug-specific Antibodies
Nanfang Hospital, Southern Medical University 14,000
Early research (Phase 1)Looking for participantsNCT06805825
What this trial is testing

The c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Who this might be right for
Gastrointestinal Stromal TumorsSmall-cell Lung CancerAdenoid Cystic Carcinoma+4 more
Novelty Nobility, Inc. 67
Large-scale testing (Phase 3)Study completedNCT02171130
What this trial is testing

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

Who this might be right for
HypoglycemiaDiabetes MellitusDrug-Specific Antibodies
Eli Lilly and Company 129
Testing effectiveness (Phase 2)Looking for participantsNCT07258407
What this trial is testing

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostatic Cancer
T.O.A.D. Oncology SA 180
Testing effectiveness (Phase 2)Study completedNCT02988817
What this trial is testing

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Who this might be right for
Ovarian CancerCervical CancerEndometrial Cancer+5 more
Genmab 306
Post-approval studies (Phase 4)Study completedNCT04370145
What this trial is testing

Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy

Who this might be right for
Cholangitis, Secondary BiliaryTreatment ComplianceAntibodies Drug Specific
Tongji Hospital 160
Testing effectiveness (Phase 2)Study completedNCT02552121
What this trial is testing

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Who this might be right for
Ovary CancerCervix CancerEndometrium Cancer+4 more
Seagen Inc. 33
Early research (Phase 1)Ended earlyNCT00006153
What this trial is testing

Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 45
Large-scale testing (Phase 3)Looking for participantsNCT04877288
What this trial is testing

Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Who this might be right for
Renal Allograft Recipients
Bristol-Myers Squibb 102
Load More Results